Arcutis Biotherapeutics Inc
ARQTHealthcare|Biotechnology|USA
$27.74
-1.03 (-3.58%)
Tangible Book
$1.40
Clinical Trials (29)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07105254 An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV) | Non-segmental Vitiligo | P2 | Recruiting | 20 | Open-label | Roflumilast topical 0.3% foam |
| NCT07077902 A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Recruiting | 10 | Open-label | Topical roflumilast 0.3% foam |
| NCT07453602 Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 | Atopic Dermatitis (AD), Eczema | P1 | Recruiting | 125 | RCT, Double-blind | ARQ-234, Placebo |
| NCT07560618 Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. | ITCH, Atopic Dermatitis | P4 | Not Yet Recruiting | 40 | Open-label | Roflumilast Cream 0.15% |
| NCT04845620 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) | Atopic Dermatitis Eczema | P3 | Completed | 652 | RCT, Double-blind | Roflumilast Cream 0.05%, Vehicle Cream |
| NCT04211363 Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Chronic Plaque Psoriasis | P3 | Completed | 439 | RCT, Double-blind | Roflumilast 0.3% cream, Vehicle Cream |
| NCT05028582 Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) | Scalp Psoriasis | P3 | Completed | 432 | RCT, Double-blind | Roflumilast Foam 0.3%, Vehicle Foam |
| NCT04211389 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Chronic Plaque Psoriasis | P3 | Completed | 442 | RCT, Double-blind | ARQ-151 0.3% cream, ARQ-151 vehicle cream |
| NCT07683806 Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Seborrheic Dermatitis | P3 | Not Yet Recruiting | 309 | RCT, Double-blind | Roflumilast Foam 0.3%, Vehicle foam |
| NCT04973228 Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) | Seborrheic Dermatitis | P3 | Completed | 457 | RCT, Double-blind | Roflumilast Foam, Vehicle Foam |
| NCT04804605 Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | Atopic Dermatitis Eczema | P3 | Completed | 1,220 | Open-label | ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% |
| NCT04773600 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) | Atopic Dermatitis Eczema | P3 | Completed | 683 | RCT, Double-blind | Roflumilast Cream, Vehicle cream |
| NCT04773587 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | Atopic Dermatitis Eczema | P3 | Completed | 654 | RCT, Double-blind | Roflumilast Cream 0.15%, Vehicle Cream |
| NCT04286607 Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Chronic Plaque Psoriasis | P3 | Completed | 333 | Open-label | Topical roflumilast |
| NCT04655313 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) | Psoriasis, Plaque Psoriasis | P2 | Completed | 20 | Open-label | ARQ-151 cream 0.3% |
| NCT04128007 Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis | Plaque Psoriasis | P2 | Completed | 304 | RCT, Double-blind | Roflumilast foam 0.3%, Vehicle foam |
| NCT03392168 Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis | Psoriasis | P1P2 | Completed | 91 | RCT, Double-blind | ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream |
| NCT04378569 Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema | Chronic Hand Eczema | P1P2 | Completed | 230 | RCT, Double-blind | ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream |
| NCT03764475 Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis | Plaque Psoriasis | P2 | Completed | 332 | Open-label | Roflumilast |
| NCT03916081 Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 136 | RCT, Double-blind | Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream |
| NCT04746911 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) | Psoriasis, Plaque Psoriasis | P2 | Completed | 10 | Open-label | ARQ-151 cream 0.3% |
| NCT04091646 Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Seborrheic Dermatitis | P2 | Completed | 226 | RCT, Double-blind | Roflumilast Foam 0.3%, Vehicle foam |
| NCT04811131 Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo | Vitiligo | P2 | Terminated | 114 | RCT, Double-blind | ARQ-252 cream 0.3%, ARQ-252 Vehicle cream |
| NCT03638258 The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis | Plaque Psoriasis | P2 | Completed | 331 | RCT, Double-blind | Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream |
| NCT06998056 Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis | Atopic Dermatitis (Eczema) | P2 | Completed | 101 | Open-label | ARQ-151 cream 0.05% |
| NCT04445987 Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Seborrheic Dermatitis | P2 | Completed | 408 | Open-label | ARQ-154 |
| NCT04156191 Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema | Atopic Dermatitis (Eczema) | P1 | Completed | 101 | Open-label | ARQ-151 cream 0.15%, ARQ-151 cream 0.05% |
| NCT04279119 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis | Plaque Psoriasis | P1 | Completed | 26 | Open-label | ARQ-151- cream 0.3% |
| NCT07340216 Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis | Psoriasis | P1 | Completed | 22 | Open-label | ARQ-154 Foam 0.3% |